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OBJECTIVE — To evaluate the association between type 2 diabetes and newly reported
Parkinson’s disease.
RESEARCH DESIGN AND METHODS — Our study included 21,841 participants in
the Physicians’ Health Study, a cohort of U.S. male physicians. Diabetes and Parkinson’s disease
were self-reported via questionnaire. We used time-varying Cox regression to calculate adjusted
relative risk (RR) for Parkinson’s disease.
RESULTS — Over 23 years, 556 individuals with Parkinson’s disease were identiﬁed. Subjects with
diabetes had an increased Parkinson’s disease risk (multivariable-adjusted RR 1.34 [95% CI 1.01–1.77]).
Theassociationremainedsigniﬁcantafterexclusionofthosewithknownvasculardisease.Thediagnosisof
diabetes was clustered around the diagnosis of Parkinson’s disease and was more apparent among men
with short diabetes duration and those without complications from diabetes.
CONCLUSIONS — Resultsofthislargeprospectivestudyinmendonotsuggestthatdiabetesis
aprecedingriskfactorforParkinson’sdisease.Whetherthepositiveassociationmaybeexplainedby
ascertainment bias or a common underlying biological mechanism remains to be established.
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A
positiveassociationbetweendiabe-
tes and Parkinson’s disease has
been found in some epidemiologic
studies (1–4) but not in others (5–7). Di-
abetesmightpromoteParkinson’sdisease
throughvariouspathways,includingsup-
pression of central dopamine levels, in-
ﬂammation, oxidative stress, and
cerebrovascular disease. We evaluated
the relationship between type 2 diabetes
andParkinson’sdiseaseindetailinalarge
prospective cohort.
RESEARCH DESIGN AND
METHODS— The Physicians’ Health
Study is a completed randomized trial of
aspirin and -carotene in the prevention
of cardiovascular disease and cancer
among 22,071 U.S. male physicians (8).
At baseline in 1982, participants were
aged 40–84 years and free of major dis-
eases. Health information was self-
reported through questionnaires at
baseline and during yearly follow-ups. A
validation study of the self-report of Par-
kinson’s disease in the Physicians’ Health
Study found it to be 90% accurate (9).
We excluded participants with Par-
kinson’s disease before study entry, de-
mentia before or within the same year as
Parkinson’s disease, diabetes before age
25 years, or missing information on dia-
betes or smoking status, leaving 21,841
individuals for analysis. We used Cox
proportional hazards models to estimate
the relative risk (RR) of Parkinson’s dis-
ease. Information on diabetes was up-
dated to incorporate incident case
subjects. We adjusted for baseline age,
smoking status, alcohol use, BMI, physi-
calactivity,andhistoryofhypertensionor
hypercholesterolemia.Westratiﬁedmod-
els by baseline smoking status, age, and
BMI.Weperformedsensitivityanalysesto
determine if diabetes characteristics or
known vascular disease (coronary heart
diseaseorstroke)affectedtheassociation.
We compared the pattern of diabetes di-
agnosis in Parkinson’s disease patients
with comorbidity-matched control sub-
jectsusingamethodpreviouslydescribed
(9). Diabetes was not included in the co-
morbidity score. Statistical calculations
were performed using SAS (version 9.1;
SAS Institute). P values are two-tailed;
P  0.05 was considered signiﬁcant.
RESULTS— Type 2 diabetes was re-
ported by 423 participants at baseline
and by 1,987 during the study. Over a
median follow-up of 23.1 years
(453,954 person-years), 556 partici-
pantsreportedincidentParkinson’sdis-
ease (median age of diagnosis 73.1
years). Men with diabetes had an in-
creased risk of Parkinson’s disease (age-
and smoking status–adjusted RR 1.34
[95% CI 1.02–1.77]) compared with
nondiabetic men. Further adjustment
did not change this risk (1.34 [1.01–
1.77]). The association between diabe-
tes and Parkinson’s disease was
signiﬁcantly modiﬁed by BMI (Pinterac-
tion  0.04), indicating increased risk
for the low BMI group (Table 1). Age
and smoking status did not modify this
association. Exclusion of patients who
developed vascular disease (n  5,418)
did not attenuate the risk (adjusted RR
1.46 [95% CI 1.00–2.13]). The highest
Parkinson’s disease risk was seen in in-
dividuals with short-duration, older-
onset diabetes without complications.
Differences in diabetes incidence be-
tween Parkinson’s disease patients and
matched control subjects was greatest
during the year of Parkinson’s disease
diagnosis and the few years prior (see
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online appendix at http://dx.doi.org/
10.2337/dc08-0688). A similar cluster-
ing was not seen for the diagnosis of
hypercholesterolemia (supplementary
Fig. 1B).
CONCLUSIONS — In this large pro-
spective study of men, a history of type 2
diabetes was associated with an increased
risk of Parkinson’s disease. The associa-
tionremainedsigniﬁcantafteradjustment
for confounders and the exclusion of par-
ticipants with known vascular disease. If
diabetes causes Parkinson’s disease, one
would expect increased duration and se-
veritytoincreaseParkinson’sdiseaserisk.
However, we found the highest risk for
Parkinson’s disease among individuals
with uncomplicated or short-duration di-
abetes, regardless of baseline age. This
was not explained by selective mortality
among those with longer diabetes dura-
tion (data not shown). Diabetic individu-
als who developed Parkinson’s disease
had a longer median time to ﬁrst compli-
cation (17.0 vs. 15.4 years), consistent
with decreased severity. Those with a
normal BMI at baseline had the highest
risk of Parkinson’s disease, suggesting a
biological pathway other then obesity.
Thus, our ﬁndings do not suggest that
diabetes is a preceding risk factor for
Parkinson’s disease.
Comparison of Parkinson’s disease
risk between case and matched control
subjectsshowedthatthedifferenceinrisk
was primarily due to a clustering of dia-
betescasesaroundthetimeofParkinson’s
disease identiﬁcation (supplementary
Fig. 1A). Thus, one explanation for the
associationmaybedetectionbiasfromin-
creased medical surveillance. However,
when we examined the diagnosis of hy-
percholesterolemia,anotherconditiondi-
agnosed by a blood test, we did not
observe a similar pattern (supplementary
Fig. 1B).
Another possible explanation is that
the development of Parkinson’s disease
may inﬂuence diabetes risk. By the time
Parkinson’s disease becomes clinically
apparent, dopaminergic cell loss has
reached 70–80% (10). Dopaminergic
neurons help motivate feeding behavior
when glucose levels are low. This feed-
back loop is mediated by insulin recep-
tors in the substantia nigra, and
postmortem studies of Parkinson’s dis-
ease show a loss of these receptors (11).
Drugs that modulate central dopamine,
such as bromocriptine, are known to af-
fect peripheral glucose control.
Changes in glucose control associated
with loss of dopaminergic function
might occur early in the course of Par-
kinson’s disease, perhaps even before
neurological symptoms develop. If Par-
kinson’s disease were a cause of diabe-
tes, one would expect an increased
incidence after the diagnosis of Parkin-
son’s disease. However, the incidence
dropped dramatically the year after Par-
kinson’s disease diagnosis (supplemen-
tary Fig. 1A). As over 25% of our
Parkinson’s disease patients were aged
80 years at diagnosis, this might re-
ﬂectdecreasedreportingfromincreased
comorbidity and mortality. Parkinson’s
disease treatment might also modulate
diabetes risk.
In conclusion, results of this large
prospective study in men do not suggest
that diabetes is a preceding risk factor for
Parkinson’s disease. The observed clus-
teringofdiabetescasesaroundthetimeof
Parkinson’s disease diagnosis suggests as-
Table 1—RRs of Parkinson’s disease according to history of type 2 diabetes
Participants (PD case
subjects) Person-years RR (95% CI)*
Pinteraction
Without
diabetes
With
diabetes
Without
diabetes
With
diabetes
Without
diabetes
With
diabetes
All participants 19,431 2,410 404,923 49,031 1.00 (ref.) 1.34 (1.01–1.77)
Baseline age (years)
55 11,684 (149) 1,247 (12) 259,924 27,489 1.00 (ref.) 1.12 (0.61–2.07) 0.81
55–64 5,140 (194) 790 (26) 103,743 15,937 1.00 (ref.) 1.57 (1.04–2.38)
65 2,607 (155) 373 (20) 41,255 5,605 1.00 (ref.) 1.25 (0.76–2.05)
BMI
25 kg/m
2 11,720 (289) 858 (31) 246,028 17,147 1.00 (ref.) 1.88 (1.28–2.77) 0.04
25 to 30 kg/m
2 7,097 (191) 1,247 (25) 147,109 25,713 1.00 (ref.) 1.14 (0.75–1.72)
30 kg/m
2 614 (18) 305 (2) 11,786 6,171 1.00 (ref.) 0.36 (0.08–1.59)
Diabetes with complications 19,431 (498) 404,923
No 1,475 (33) 30,981 1.00 (ref.) 1.63 (1.14–2.33) 0.0002
Yes 935 (25) 18,050 1.00 (ref.) 1.10 (0.74–1.64)
Diabetes duration (years) 19,432 (498) 404,931
5 562 (22) 11,048 1.00 (ref.) 7.17 (4.59–11.20) 0.0001
5–9 631 (14) 12,945 1.00 (ref.) 2.03 (1.22–3.36)
10–14 482 (7) 9,921 1.00 (ref.) 0.82 (0.42–1.60)
15 734 (15) 15,109 1.00 (ref.) 0.73 (0.45–1.18)
Age at onset of diabetes (median) 19,431 (498) 404,923
63.7 1,213 (22) 24,654 1.00 (ref.) 1.18 (0.78–1.79) 0.0002
63.7 1,197 (36) 24,377 1.00 (ref.) 1.49 (1.04–2.11)
Data are n( n ) unless otherwise indicated. *Adjusted for the following baseline variables: age (continuous), smoking status (never, past, or current), alcohol use
(rarely, weekly, or daily), BMI (25 kg/m
2, 25 to 30 kg/m
2,o r30 kg/m
2), physical activity vigorous enough to work up a sweat (1–3 times/month or 1–3
times/month), hypertension (history of treatment or blood pressure 140 systolic or 90 diastolic), and cholesterol levels (history of treatment or total cholesterol
240). PD, Parkinson’s disease.
Type 2 diabetes and Parkinson’s disease risk
2004 DIABETES CARE, VOLUME 31, NUMBER 10, OCTOBER 2008certainment bias or an underlying com-
mon biological mechanism. Future
studies are warranted to further unveil
this association.
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